Gerald Andriole, MD

389 posts

Gerald Andriole, MD banner
Gerald Andriole, MD

Gerald Andriole, MD

@uropro

Chief Medical Officer, Prostatype Genomics

Katılım Ekim 2009
934 Takip Edilen1.8K Takipçiler
Gerald Andriole, MD retweetledi
Laura Caba
Laura Caba@Caba_L·
A toast 🥂 to the 50th Anniversary of the Winter Urologic Forum! 💫 Always a great meeting! @ColumbiaUrology @UCDavisUrology Vanderbilt Urology
Laura Caba tweet media
English
1
4
11
834
Gerald Andriole, MD retweetledi
UroToday.com
UroToday.com@urotoday·
Phase 1 study evaluates bone metastasis resolution with SYNC-T therapy SV-102. @uropro @ProstatypeAB joins @zklaassen_md @GACancerCenter SYNC-T therapy SV-102 for metastatic prostate cancer. The treatment combines one-minute cryolysis of tumor tissue with immediate infusion of a four-component immunoadjuvant to generate tumor-specific T cell responses. #WatchNow > bit.ly/3MuSxKr
English
0
3
12
935
Matt Cooperberg
Matt Cooperberg@dr_coops·
Adam Cole @pathnetlab at @UrologyUS winter meeting showing off near-future future "pathology porn": 3D multimodal analysis of full uncut biopsy cores, with AI weighing in 🤯
English
2
3
18
3.3K
Gerald Andriole, MD
Gerald Andriole, MD@uropro·
Prostatype P-score demonstrated superb risk classification of Prostate Cancer in a diverse US population. Very useful tool for men considering Active Surveillance and the intensity of surveillance. Low risk men had no PCSM! @nature.com/pcan/
Gerald Andriole, MD tweet media
English
0
0
4
151
UroToday.com
UroToday.com@urotoday·
Phase 1 study evaluates bone metastasis resolution with SYNC-T therapy SV-102. @uropro @ProstatypeAB joins @zklaassen_md @GACancerCenter SYNC-T therapy SV-102 for metastatic prostate cancer. The treatment combines one-minute cryolysis of tumor tissue with immediate infusion of a four-component immunoadjuvant to generate tumor-specific T cell responses. #WatchNow > bit.ly/3MuSxKr
English
2
2
2
553
Gerald Andriole, MD retweetledi
Syncromune®
Syncromune®@syncromune·
Thank you #SUO25. We were proud to share Phase 1 SYNC-T data showing 54% of metastatic prostate cancer patients had complete resolution of bone metastases and favorable tolerability. SYNC-T is now being studied for mCRPC in the Phase 2 LEGION-100 trial. Details: bit.ly/48jYaU5
Syncromune® tweet media
English
0
1
1
232
Gerald Andriole, MD retweetledi
Julian Chavarriaga
Julian Chavarriaga@chavarriagaj·
#SUO25 @uropro presents SYNC-T SV-102 for mPCa 🧬 Image-guided intratumoral immunotherapy targeting 4 immune axes 👥 n=15 (Phase 1) | post-ARPI or hormone-declined | bone mets in 87% 🔹 ORR: 87% | CR: 53% 🔹 Bone mets resolved in 7/13 pts incl. >50 lesions in 1 case 🛡️ 95% Grade 1–2 AEs | no Gr 4/5 ✅ Early signal for durable, systemic immunity via local delivery @UroToday @UroOnc
Julian Chavarriaga tweet mediaJulian Chavarriaga tweet mediaJulian Chavarriaga tweet media
English
0
4
8
662
Gerald Andriole, MD retweetledi
Syncromune®
Syncromune®@syncromune·
Syncromune® Inc. Presents Positive Results from SYNC-T® Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025 - 87% ORR - 53% CR - 100% DCR - 14.2 months rPFS - 80% survival after 17.2 month median follow-up globenewswire.com/news-release/2…
English
0
1
3
1.8K
Gerald Andriole, MD retweetledi
Syncromune®
Syncromune®@syncromune·
Stop by the Syncromune booth at #ASCO25 to learn more about our LEGION-100 Phase 2a trial of SYNC-T Therapy SV-102 for #mCRPC. Now enrolling and recruiting clinical trial sites. #LEGION100 #ProstateCancer
Syncromune® tweet media
English
0
1
0
795
Gerald Andriole, MD retweetledi
Syncromune®
Syncromune®@syncromune·
Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting #ASCO25 globenewswire.com/news-release/2…
English
0
1
4
842
Elon Musk
Elon Musk@elonmusk·
Cool
Mario Nawfal@MarioNawfal

🚨X OUTPERFORMS FACEBOOK AND INSTAGRAM According to the traffic monitoring site Similarweb, X smashed it out of the ballpark with more visits worldwide than Instagram and Facebook. X had 13.14 billion views throughout June, compared to Facebook’s 12.44 billion and Instagram’s 5.798 billion. X had almost 3 times the number of unique visitors than Facebook. X had 3.127 billion unique visitors. Facebook had 1.050 billion unique visitors. Instagram had 919 million unique visitors. Source: Similarweb

English
7.8K
12.6K
113K
46.9M
Gerald Andriole, MD
Gerald Andriole, MD@uropro·
Prostatype Genomics AB US subsidiary Prostatype Genomics, Inc. has been accredited by the CAP (College of American Pathologists) Laboratory Accreditation Program!
English
0
0
2
375
Gerald Andriole, MD
Gerald Andriole, MD@uropro·
Dr. Gerald Andriole presented Prostatype Genomic Classifier's ability, with a significant AUC of .88 (Gleason score ≥4+3and/or pT3), to predict adverse pathology at RP. 📷
English
0
1
1
649
Gerald Andriole, MD retweetledi
STLToday Sports News
STLToday Sports News@STL_SportsNews·
Gordo ranks area hoops: Cloud forms over Illinois, SLU gets huge boost dlvr.it/T0qfqh
English
0
2
0
4.9K
Gerald Andriole, MD retweetledi
FOCAL+ 2025
FOCAL+ 2025@therapy_focal·
#FOCAL2023 starts TOMORROW! Make sure to follow all of our awesome faculty! @arvinkgeorge @AbhinavSidana @Freddie_Hamdy @DrJohnMDiBi @uropro @LetDdiceFlyHigh @ezebecher @DrSteveCanfield @peterchiu_uro @ChughtaiMD @BehfarEhdaieMD @FryeUroOnc @gupta_go @amy_krambeck @fleauxdoc @oncostan @lissmike @RaisBahrami @Rowe_NuclearMed @TaimurShah @DrilyaSobol1 @Dr_sprenkle @tanejauro @radiolobt @vermasadhna @vourganti @Dr_KevinZorn
FOCAL+ 2025 tweet media
English
2
12
34
5.7K

Keşfet

@ColumbiaUrology @UCDavisUrology @ProstatypeAB @zklaassen_md @GACancerCenter @dr_coops @PathNetLab @UrologyUS